Top Edinburgh Biotech Companies (18)
Don't see your company?
Create a company profile
EnteroBiotix is a leading microbiome therapeutics platform company that is focussed on transforming the standard of care for patients battling debilitating diseases and infections linked to disruptions to structure and function of the gut microbiome
MiAlgae aims to revolutionize the current livestock and pet feed industries by producing microalgae rich in polyunsaturated fatty acids (PUFAs) to offer as a replacement to fishmeal in feed. 🚫🐟 Feed suppliers are in need of this alternative to fishmeal due to declining wild fish stocks and rising demand for Omega-3s. MiAlgae has developed an environmentally beneficial, effective, and simple solution of producing microalgae which delivers the required nutrients to livestock and pets without the need for fish. ♻️ Our zero-waste solution recycles the nutritional co-products from whisky production to grow Omega-3 rich microalgae, returning clean water in the process. 🌍 Our mission is to create a product that will contribute substantially towards the sustainable production of livestock, a prerequisite to fulfilling the needs of the growing world population. 💡Please check us out and follow us on: -https://www.twitter.com/mialgae -https://www.instagram.com/mialgae/
A UK biotech startup company passionate about independent living. Hand weakness affects millions in the UK alone, and we have a solution which will help
Developing precision medicines to modulate macrophages for the treatment of cancer.
Providing predictive analytics from suspended-cells through our unbiased cytometry technology, Cytomos® Dielectric Spectroscopy: CDS™
Carcinotech is a MedTech company with expertise in manufacturing 3D printed micro-tumours using patient-derived biopsies, primary cells, immune cells and cancer stem cells. Carcinotech’s advanced models provide a platform for rapid, ethical, and accurate drug screening, pre-clinical and personalised medicine testing. Working with global partners, leading pharma companies, surgeons, pathologists, clinicians, and industry-leaders, the goal is to accelerate drug screening and enable delivery of more effective cancer treatments to market. Access to Carcinotech’s robotic and automated manufacturing allows for accelerated production, with models offering high-throughput capabilities. We are a team of like-minded, highly-experienced and determined individuals, all sharing a vision for success. Learn more about our models, get in touch.
Kynos Therapeutics is a clinical-stage private company developing an innovative pipeline of first-in-class kynurenine 3-monooxygenase (KMO) inhibitors. KMO plays a major role in the regulation of inflammation, acting at the interface between inflammation, immunity and metabolism. Inhibition of KMO has therapeutic potential in both acute inflammatory conditions such as acute kidney injury and acute pancreatitis and in chronic immuno-inflammatory disorders. Spun out from the University of Edinburgh, Kynos leverages a decade of drug discovery research on KMO inhibitors originally co-developed through a collaboration between GSK and the University of Edinburgh and now exclusively licensed to Kynos. Based in Edinburgh, UK, the company is backed by founding investor Epidarex Capital as well as IP Group plc and Scottish Enterprise with additional non-dilutive funding from Innovate UK. Kynos Therapeutics Ltd. is a Private Limited Company Registered in England and Wales, Company number 12501037
Based outside Edinburgh, Roslin Technologies Limited is an ambitious food and agriculture technology company which creates disruptive biotechnologies to improve how proteins are made. Our core capabilities lie in developing and commercialising a suite of unique animal stem cells and resources for the nascent global cultivated meat industry. We were the first company to commercialise pluripotent stem cells which continually self-renew and are able differentiate into the fat and muscle tissue required in the cultivated meat industry. In addition, we are now focussing our R&D on addressing key challenges in the sector including production cost reduction and process scale-up. We have developed unique animal cells that work; our cells can self-renew forever and differentiate into any tissue, including muscle and fat. Our cells are favourable for cultivated meat production since they address consumer concerns, make meat more affordable, and simplify regulatory approvals. Besides cells for cultivated meat, we continue to look for other biotechnologies that help us make protein production more sustainable.
Arrayjet provides microarray instruments and services to the pharmaceutical, diagnostic and life science industries. Our unique inkjet platform combines the fastest and most reliable instrumentation on the market with the versatility to print any biological sample type onto any solid substrate. Applications range from antibody characterization to gene expression profiling and drug discovery. >> High Throughput Screen samples faster with high-speed, high-density, high-capacity microarray printing using patented inkjet technology. >> Consistent Tight environmental controls and real-time quality assurance ensure array reproducibility. >> Cost-Effective Save time and money with increased throughput, lower maintenance requirements, walkaway operation and minimised sample use. Customer relationships drive our innovation. Our technology is cutting edge, but it is our partnerships that deliver long-term value for clients. Get started by booking a technical consultation today. Instruments and services are delivered from our ISO 13485:2016 compliant facility in Scotland
Wobble Genomics is a pioneering healthcare and biotechnology company specialising in long-read RNA sequencing. Its innovative Level-Up biochemical technology enhances the detection of low-abundance RNA sequences, allowing scientists to capture all unique full-length RNA sequences in any sample. Paired with its TAMA bioinformatic technology, Wobble optimises the identification of low-level signals, using RNA biology to drive deeper insights from sequencing data
RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the groundbreaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones, including being among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR-edited stem cell-based therapy for a major disease to marketing authorization. Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialization and deliver life-saving Cell and Gene Therapies worldwide. Discover more about our services at www.roslinct.com.
ŌGI Bio offers our customers in the microbiology sector an affordable route into the automation of routine microbial culturing. We do so through a unique modular, retrofittable device that allows customers to choose the specific functions they require for their processes as and when they identify them. This gives our customers a flexible base from which to accelerate their innovation by increasing their R&D throughput.
At Green Bioactives, we are passionate about making a positive impact on the world by developing sustainable plant-based products using our innovative biomanufacturing platforms. Our proprietary Plant Cell Culture Technology has enabled us to revolutionise the way that plant derived ingredients are produced, using sustainable methods of cultivation without the need to destroy trees and habitats. This means we can produce ingredients in a natural and sustainable way that may otherwise be challenging to obtain at the required volume. We work with SMEs and multinational companies to help develop and manufacture natural plant-derived product ingredients for use in nutraceutical and cosmetic products. We offer co-development solutions where we can work in partnership with you to create the right solution for your business, and for your customers. We are a highly collaborative team of scientists, industry experts and entrepreneurs, all united by our mission to save the environment and revolutionise the industry of biotechnology. Visit our website to discover more about our plant-based product solutions and Plant Cell Culture Technology.
We’re developing the next generation of ultrafast laser sources for scientific research and industrial applications worldwide. We’ve fused together solid-state and fiber-based technology to develop a range of fixed wavelength and tunable laser sources. Our robust and compact systems ensure high stability and optimal efficiency, whereas our IP protected manufacturing know-how enables Chromacity to offer systems at affordable price points, without compromise on performance. Our highly versatile lasers are ideal for a diverse range of industrial and scientific applications including: life science imaging, spectroscopy, fundamental research, security & defence, environmental sensing and semiconductor failure analysis. For further details about our products and other future developments visit our website www.chromacitylasers.com or email [email protected].
Celtic Renewables patented technology converts low-value byproducts, residues and waste into high-value green chemicals which directly displace chemicals made from gas and oil in the manufacturing process and lower the carbon footprint of everyday products like skin creams, nail varnish, household cleaning products, paints, medicines and vitamins.
We are a Bioinformatics Provider with clients in the UK, Europe and America. With over 10 years of experience in supporting scientists, researchers and bioinformaticians in data analysis, we have an extensive experience in handling all types of datasets for drug discovery & development, diagnostics, agricultural research, veterinary medicine and applied research across all species. Our specialised team of bioinformaticians, statisticians and biologists are able to analyze and interpret any genomic, transcriptomic, proteomic & metabolomic data, independent of the platform used. We are very well appreciated among our clients for our proprietary computer solutions that allow parallelisation of large datasets analysis that saves processing time and avoids the complications that arise when analyzing data in batches. Results of the analysis are always presented in a secure web report that is complete with all references and results. Types of services offered by FIOS: ● Technology/Platform Selection ● Study Design & Biostatistics ● Data QC and Pre-processing ● Biomarker Identification & Validation ● Genomic Signature Development ● Data Visualisation ● Preclinical Safety & Toxicology Investigations ● Clinical Trial Analysis ● Drug Repurposing For more info, get in touch: https://www.fiosgenomics.com/contact-us/ Twitter: @fiosgenomics Facebook: https://www.facebook.com/fiosgenomics/ Office Phone Number: +44 (0)131 322 3770 Office Address: Fios Genomics Ltd, BioCube 1, 13 Little France Road, Edinburgh BioQuarter, Edinburgh, EH16 4UX
BIOCAPTIVA is developing the BioCaptis, a revolutionary medical device which has the potential to transform liquid biopsy testing for cancer management, by improving early diagnosis and monitoring of disease and enhancing clinical trial data of cancer patients. The BioCaptis captures up to 100x more cell free DNA (cfDNA) than a venous blood draw, yielding cfDNA in high quality and quantity for testing, addressing the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BIOCAPTIVA was founded in 2021 when it spun out from the University of Edinburgh. BIOCAPTIVA is based in Edinburgh and backed by Archangels Scottish Enterprise, Cancer Research Horizons, the new innovation engine of Cancer Research UK and Old College Capital, the University of Edinburgh’s in-house venture investment fund. For more information, please visit www.biocaptiva.com
At Rhizocore, we develop technologies to grow symbiotic fungi that enhance the growth, resilience, and carbon sequestration potential of newly planted forests and woodlands. Whether it is for woodland restoration, commercial productivity, increasing tolerance to environmental stresses or capturing more carbon, our unique approach for growing locally-sourced mycorrhizal fungi ensures local adaptability to suit our customer's sites and needs. For more information email: [email protected]
Work Your Passion. Live Your Purpose.
